Related Experiment Video

Updated: Mar 25, 2026

A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.9K

Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children

Leelawadee Techasatian1, Patcharee Komwilaisak2, Sunee Panombualert2

  • 1Division of Dermatology, Department of Pediatric, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Acta Paediatrica (Oslo, Norway : 1992)
|February 27, 2016
PubMed

Insights

Propranolol effectively treats infantile haemangiomas, with rapid responses observed. Combining propranolol with prednisolone showed no significant difference in outcomes, but monitoring for side effects like hypoglycemia is crucial.

Area of Science:

  • Pediatric Dermatology
  • Vascular Biology
  • Pharmacology

Background:

  • Infantile haemangiomas are common benign vascular tumors in children.
  • Early intervention is key for optimal treatment outcomes.
  • Propranolol has emerged as a primary treatment option.

Purpose of the Study:

  • To evaluate the efficacy and safety of propranolol for infantile haemangiomas.
  • To compare propranolol monotherapy with combination therapy including prednisolone.

Main Methods:

  • Retrospective chart review of 53 patients with infantile haemangiomas.
  • Analysis of treatment response and adverse events following oral propranolol administration.
  • Comparison of outcomes between monotherapy and combination therapy.

Main Results:

  • 91.5% of patients showed treatment response within two weeks of propranolol initiation.
  • All patients achieved desired treatment outcomes by two months.
  • No significant difference in efficacy between propranolol monotherapy and combination therapy with prednisolone.
  • Adverse events (hypoglycemia, hypotension) occurred in 5.6% of cases with dose escalation.

Conclusions:

  • Oral propranolol is an effective treatment for infantile haemangiomas.
  • Combination therapy with prednisolone does not offer significant advantages over monotherapy.
  • Close monitoring for hypoglycemia and hypotension is recommended during propranolol treatment.
  • Further long-term studies are needed to fully understand propranolol's role in infantile haemangioma management.
Abstract

Keywords:
HypoglycaemiaHypotensionInfantile haemangiomasPrednisolone propranolol

More Related Videos

Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles03:06

Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles

Published on: December 22, 2023

1.2K
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.7K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
595
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
633
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
544